UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Emerging small-molecule treatments for multiple sclerosis: focus on B cells

Gregson, A; Thompson, K; Tsirka, SE; Selwood, DL; (2019) Emerging small-molecule treatments for multiple sclerosis: focus on B cells. F1000Research , 8 , Article 245. 10.12688/f1000research.16495.1. Green open access

[thumbnail of Gregson_-_david_selwood.pdf]
Preview
Text
Gregson_-_david_selwood.pdf - Published Version

Download (1MB) | Preview

Abstract

Multiple sclerosis (MS) is a major cause of disability in young adults. Following an unknown trigger (or triggers), the immune system attacks the myelin sheath surrounding axons, leading to progressive nerve cell death. Antibodies and small-molecule drugs directed against B cells have demonstrated good efficacy in slowing progression of the disease. This review focusses on small-molecule drugs that can affect B-cell biology and may have utility in disease management. The risk genes for MS are examined from the drug target perspective. Existing small-molecule therapies for MS with B-cell actions together with new drugs in development are described. The potential for experimental molecules with B-cell effects is also considered. Small molecules can have diverse actions on B cells and be cytotoxic, anti-inflammatory and anti-viral. The current B cell-directed therapies often kill B-cell subsets, which can be effective but lead to side effects and toxicity. A deeper understanding of B-cell biology and the effect on MS disease should lead to new drugs with better selectivity, efficacy, and an improved safety profile. Small-molecule drugs, once the patent term has expired, provide a uniquely sustainable form of healthcare.

Type: Article
Title: Emerging small-molecule treatments for multiple sclerosis: focus on B cells
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.12688/f1000research.16495.1
Publisher version: https://doi.org/10.12688/f1000research.16495.1
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: B cells, MS, Multiple sclerosis, small molecule drugs, sustainable healthcare
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Wolfson Inst for Biomedical Research
URI: https://discovery.ucl.ac.uk/id/eprint/10070579
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item